PTU - Polskie Towarzystwo Urologiczne
list of articles:

DELAYED AND DISRUPTED HORMONAL TREATMENT OF PATIENTS WITH PROSTATIC CARCINOMA
Article published in Urologia Polska 1988/41/4.

authors

Jan Szymanowski, Zofia Kasprzycka, Ewa Koźmińska
Z Oddziału Urologii Szpitala Bielańskiego w Warszawie Ordynator: dr n. med. J. Szymanowski

summary

The subject of the article is critical evaluation of the results of delayed and disrupted monitored hormonal treatment of patients with prostatic carcinoma by means of diethylostilbestrol, diphosphate and bromocriptine. Following Principles were adopted: 1) therapy was started only suffering or/and with an increased level of neoplasm markers in the blood serum, particularly acid phospha­tase and its prostatic fraction, 2) minimal doses of drugs reducing phosphatase con­centrations and giving relief were used. 3) therapy was stopped in patients without ailments and with normal values of markers.
Within 65.0 months of observation, among 153 patients with prostatic carcinoma 69 (45.1%) died, 84 (54.9%) patients are alive and 54 patients (35.3%) live without symptoms of neoplasm.
Delayed and disrupted hormonal treatment is a better method in Comparison with other forms of continuous treatment by means of oestrogens only.

references

  1. 1. Ahmed S.R., Grant J.B.F., Shalet S.M., Howell A., Costello C.B., Weather-son T., Blackloek. N. J.: A new hormonal therapy for prostatic cancer: Long-term clinical and hormonal response. Brit. J. Urol., 1986, 58, 5, 534. ? 2. Baranowska B., Jeske W,, Szymanowski J., Piechna K.: L'accroissement de la secretion de la pro-lactine apres le freinage des recepteurs dopaminoergiques par le metoclopramide chez les malades porteurs d'un cancer de la prostate. J. d'Urol., 1983, 89, 8, 601. ? 3. Baranowska B., Szymanowski J., Jeske W.: Wpływ bromokryptyny na wy­dzielanie prolaktyny po zablokowaniu receptorów dopaminergicznych metoklopra­midem u chorych z rakiem gruczołu krokowego leczonych estrogenami. Endokr. Pol., 1984, 35, 4, 211. ? 4. Fair W. R.: Hormonal therapy of advanced prostatic can­cer. J. Urol., 1986, 136, 3, 653. ? 5. Haapiainen R., Ranniko S., Alfthan O.: Compa­rison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of National, prospective Prostatic Cancer Study. Brit. J. Urol., 1986, 58, 5, 528. ? 6. Jeromin L., Wiśniewski J., Rożniecki M., Janiak Z., Bortkiewicz J.: 5-letnia obserwacja kliniczna chorych na raka stercza leczonych fos­festrolem i bromokryptyną. Urol. Pol., 1984, 37, 3, 189. ? 7. Jeromin L,: Zastoso­wanie bromokryptyny w leczeniu raka gruczołu krokowego. Urol. Pol., 1982, 35, 3? 4, 141. ? 8. Leńko J.: Rak stercza. Urol. Pol., 1984, 37, 4, 245. ? 9. Reiner W. C, Scott W. W., Eggleston J. C, Walsh P. C: Long-term survival after hormonal thera­py for stage D prostatic cancer. J. Urol., 1979, 122, 2, 183. ? 10. Schroeder F. H., de Voogt H. J.: Steroid receptors, metabolism and prostatic cancer. Excerpta Medica, Amsterdam, 1979.
  2. 11. Zieliński J.: Sprawozdanie z XXXVIII Zjazdu Niemieckiego Towarzystwa Urologicznego (Wurzburg 23?28 września 1986 r.). Urol. Pol., 1987, 40, 2, 153.